Prime Medicine Inc. (PRME)
PRME trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.32
-8.03% on the day
Market cap
$602.2M
Small cap
Revenue · 2025
$4.6M
+55.3% on 2024
Net income · 2025
-$201.1M
-4342.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | PRME on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001894562 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.6M |
| Net income | -$201.1M |
| Operating income | -$208.3M |
| Net margin | -4342.4% |
| Operating margin | -4498.1% |
| Revenue growth | +55.3% |
| Cash | $63.0M |
| Total assets | $342.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 130.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-03-03 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 298 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.9% |
| 1 month | -1.8% |
| 3 months | -4.2% |
| Year to date | -11.1% |
| 1 year | -45.4% |
| From 52-week high | -51.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | $5.82 | -13.26% | $624.1M |
| AURA | Aura Biosciences Inc. | $6.27 | -4.13% | $650.2M |
| ETRA | Electra Therapeutics Inc. | $8.61 | -7.62% | $540.4M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | +0.89% | $672.0M |
| DBVT | DBV Technologies S.A. | $9.03 | -5.45% | $534.7M |
| FDMT | 4D Molecular Therapeutics Inc. | $12.36 | -4.92% | $682.8M |
| VALN | Valneva SE | $5.56 | -6.24% | $527.6M |
| CADL | Candel Therapeutics Inc. | $9.27 | -5.21% | $709.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier